Urolithin A has attracted growing scientific interest for its ability to stimulate mitophagy: a cellular process that clears out damaged mitochondria and supports the renewal of healthier ones. As more people consider supplementing with it, a reasonable question follows: is urolithin A safe to take over the long term?
The honest answer is that the evidence base is still developing. Most human studies to date have been relatively short in duration, and many mechanistic findings come from laboratory or animal settings. This article summarizes what current research does and does not tell us, without overstating the conclusions.
Key Takeaways
- Urolithin A is proposed to stimulate mitophagy, the cellular process for removing damaged mitochondria; most of the evidence is from cells, worms and mice [9][10][11].
- Many people can make urolithin A from ellagitannin-rich foods using gut bacteria, but production varies widely; in 100 US adults, 33% could not convert pomegranate juice to urolithin A and 27% converted poorly [12][1].
- Short-term human trials suggest it is reasonably tolerated, but multi-year safety data in humans does not yet exist in the published literature reviewed here.
- Urolithin A induced cellular senescence in human colon cancer cells in laboratory settings; at a high lab concentration it also slowed division of human skin cells [15][2]a finding that is context-dependent and should not be generalized.
- Supporting gut microbiome diversity is a plausible, lower-risk approach to increasing natural urolithin A production [3].
How Urolithin A Works: The Mitophagy Mechanism
Mitochondria are the energy-producing organelles in every cell. With age and metabolic stress, they accumulate damage, and dysfunctional mitochondria are increasingly recognized as a central driver of cellular aging and decline [4]. Mitophagy is the selective process by which cells identify and remove these damaged mitochondria, making way for the generation of healthier replacements.
Urolithin A is one of the most studied natural compounds that activates this mitophagy pathway. Understanding this mechanism matters for safety because it means urolithin A is interacting with fundamental cell biology, which is precisely why both its potential benefits and its theoretical risks deserve careful examination rather than dismissal.
Where Urolithin A Comes From: Gut Microbiota as the Source
Most people do not absorb urolithin A directly from food. Instead, gut bacteria convert dietary ellagitannins (found in pomegranates, walnuts, and certain berries) into urolithin A and related compounds. This conversion varies considerably between individuals depending on the composition of their microbiome. Research tracking walnut consumption over three days found that people fall into distinct ‘urolithin metabotypes,’ with some producing urolithin A efficiently while others produce little or none [1].
Research note: As summarised by FDA, the notifier states that no toxicologically significant effects were seen in a 28-day rat study at diets up to 4,165 mg/kg body weight per day in males and 4,706 mg/kg in females, the highest levels tested [17].
Some interventions aimed at the gut microbiome have been linked to higher urolithin A output, but the evidence is thin [3]. A randomized, placebo-controlled trial in 32 healthy adults of a synbiotic that contained pomegranate extract raised urinary urolithin A 12-fold at day 7 and 49-fold at day 91 versus placebo; because the product supplied an ellagitannin source, this does not show that microbiome diversity alone raises urolithin A [3]. A follow-up study in people recovering from antibiotic courses found similar benefits for microbiome recovery and gut barrier integrity [5]. These findings suggest that promoting the gut bacteria responsible for urolithin A synthesis is a plausible indirect approach, though they do not speak directly to the safety of supplemental urolithin A itself.
Cellular Effects: Promising Signals and One Important Nuance
Much of the safety-relevant cellular research on urolithin A comes from laboratory studies rather than long-term human trials. One study examined urolithin A’s effects on human colon cancer cells and found that it, unlike some related urolithins, induced p53-dependent cellular senescence in those cancer cells; healthy cells were not the focus of that study [15][2]. Cellular senescence in cancer cells is generally considered a desirable outcome because it can halt uncontrolled proliferation.
However, this finding also illustrates the complexity of interpreting cell-level data. Senescence in cancer cells is different from senescence in healthy cells, and laboratory results do not automatically translate into the same effects in a living human body. The authors were studying an anti-cancer mechanism, not a safety problem, but the nuance underscores why long-term human data would be more informative than extrapolating from isolated cell experiments.
Urolithin A also interacts with the aryl hydrocarbon receptor (AHR), a cellular sensor that plays a role in regulating intestinal immunity and inflammation [6]. AHR signaling is an active area of research, and how chronic activation or modulation of this pathway by urolithin A affects human health over years remains an open question.
Animal and Preclinical Findings
Some preclinical work has explored urolithin A’s effects beyond the gut. An animal study found that urolithin A attenuated neurological effects of a parasitic infection and altered immune responses to specific environmental stimuli [7]. While this points to a potentially broad biological reach, findings from animal models, particularly under disease conditions, should not be directly applied to predicting effects in healthy humans.
Researchers have also explored novel delivery methods for urolithin A, including inhalable microparticle formulations designed to target the lungs [8]. This work is in very early stages and reflects scientific curiosity about the compound’s range of applications, not evidence of established safety or efficacy for pulmonary use. It is mentioned here only to illustrate how early-stage much of the research landscape remains.
What Long-Term Safety Evidence Is Still Missing
The evidence reviewed here does not include multi-year randomized controlled trials in humans assessing hard safety endpoints such as organ function, cancer incidence, hormonal changes, or all-cause mortality. The studies available are predominantly short-term interventional trials, mechanistic cell studies, and animal experiments. This is not a critique of the research that exists: it accurately reflects where the science currently stands.
Short-term safety data do exist for urolithin A itself. In a 4-month trial of 88 middle-aged adults, 102 adverse events were reported by 45 participants (42 on placebo, 24 on 500 mg, 36 on 1,000 mg) and the authors judged it safe and well tolerated; in a 28-day trial of 50 adults, only nine adverse events were recorded and kidney function and liver enzymes did not change significantly. Both trials were funded by Amazentis, and a review of published data has argued that urolithins deserve further evaluation for high-dose toxicity [13][14][16].
Because urolithin A affects mitochondrial dynamics and interacts with signaling receptors like AHR, long-term data would be particularly valuable for understanding cumulative effects in older adults, people with existing metabolic conditions, and those taking medications that affect mitochondrial function or immune regulation. None of the studies in the current evidence base address these populations over an extended time horizon.
It also bears noting that because most people rely on gut bacteria to produce urolithin A from food, and because individual production varies widely [1], the effective dose from supplementation versus dietary sources is difficult to compare. Long-term safety assessments of a synthetic supplement may not map directly onto the safety profile of endogenously produced urolithin A.
Practical Considerations for People Interested in Urolithin A
For healthy adults, supporting gut microbiome diversity through diet, including foods rich in ellagitannins like pomegranates and walnuts, is a low-risk way to modestly increase natural urolithin A production. Evidence from a synbiotic trial that included pomegranate extract suggests the gut-conversion gap can be changed (by day 91 all synbiotic participants could convert polyphenols to urolithin A versus 44.4% of the placebo arm), but it does not show that microbiome diversity alone is responsible [3].
For those considering supplemental urolithin A, the current evidence suggests it is reasonably tolerated in short-term studies, but the absence of long-term human safety data means it cannot be classified as proven safe over years. As with any supplement that interacts with fundamental cell biology, individuals with a history of cancer, those taking immunosuppressants, and people with significant comorbidities should discuss use with a healthcare provider before starting.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The research reviewed here is predominantly from short-term trials, cell studies, and animal experiments: long-term human safety data for supplemental urolithin A is not yet established in the published literature cited. People who are pregnant, immunocompromised, have a history of cancer, or take medications affecting mitochondrial or immune function should consult a qualified healthcare provider before using urolithin A supplements. Nothing in this article constitutes medical advice.
Frequently Asked Questions
Are there any human trials showing urolithin A is safe?
Short-term human trials of urolithin A itself have been conducted. In a 4-month trial of 88 middle-aged adults the authors judged 500 mg and 1,000 mg a day safe and well tolerated, and a 28-day trial of 50 adults found no significant changes in kidney function or liver enzymes [13][14]. However, the evidence reviewed here does not include published multi-year safety trials specifically evaluating supplemental urolithin A as a standalone compound.
Does urolithin A have any effects on cancer cells?
One laboratory study found that urolithin A, but not other related urolithins, triggered p53-dependent cellular senescence specifically in human colon cancer cells [2]. This is a cell-level finding under controlled conditions and does not constitute evidence of anti-cancer effects in humans, nor does it indicate a safety concern for healthy cells based on this study alone.
Can everyone produce urolithin A from food?
No. Research tracking walnut consumption found that individuals fall into distinct urolithin metabotypes, meaning some people’s gut bacteria efficiently convert ellagitannins into urolithin A while others produce very little [1]. This variability is why some researchers have explored direct supplementation as an alternative.
How does urolithin A relate to mitochondrial health?
Urolithin A is thought to promote mitophagy: the selective removal of damaged mitochondria. Dysfunctional mitochondria accumulate with age and are increasingly recognized as contributors to cellular decline [4]. By stimulating their clearance, urolithin A may support mitochondrial quality, though long-term human evidence for this benefit remains limited.
What is the AHR receptor and why does it matter for urolithin A safety?
The aryl hydrocarbon receptor (AHR) is a cellular sensor involved in regulating intestinal immunity and inflammation responses [6]. Urolithin A interacts with this pathway, which is of interest for gut health but also means that the long-term effects of repeated AHR modulation by urolithin A in humans are not yet fully characterized.
Should people with health conditions avoid urolithin A?
This article cannot provide medical advice. However, because urolithin A interacts with mitochondrial dynamics and immune signaling pathways, people with a history of cancer, significant immune conditions, or those on medications affecting these systems should consult a healthcare provider before use. The current evidence base does not support definitive safety conclusions for these groups over the long term.
References
- GarcÃa-Mantrana I et al. Urolithin Metabotypes Can Determine the Modulation of Gut Microbiota in Healthy Individuals by Tracking Walnuts Consumption over Three Days. Nutrients (2019). PMID 31623169
- Giménez-Bastida JA et al. The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2020). PMID 32179165
- Napier BA et al. Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Nutrients (2025). PMID 40944126
- Marei HE et al. Mitochondria at the heart of aging: structure, function, and failure. Journal of translational medicine (2026). PMID 42032617
- Napier BA et al. Multi-Species Synbiotic Supplementation After Antibiotics Promotes Recovery of Microbial Diversity and Function, and Increases Gut Barrier Integrity: A Randomized, Placebo-Controlled Trial. Antibiotics (Basel, Switzerland) (2026). PMID 41750436
- Pernomian L et al. The Aryl Hydrocarbon Receptor (AHR) as a Potential Target for the Control of Intestinal Inflammation: Insights from an Immune and Bacteria Sensor Receptor. Clinical reviews in allergy & immunology (2020). PMID 32279195
- Tan S et al. Urolithin-A attenuates neurotoxoplasmosis and alters innate response towards predator odor. Brain, behavior, & immunity – health (2020). PMID 34589880
- Shafi H et al. Advanced Spray-Dried Inhalable Microparticles/Nanoparticles of an Innovative Mitophagy Activator for Targeted Lung Delivery: Design, Comprehensive Characterization, Human Lung Cell Culture, and In Vitro Aerosol Dispersion Performance. ACS pharmacology & translational science (2024). PMID 39539257
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
- Gao Z et al. Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2. International journal of biological sciences (2022). PMID 35342347
- Peter M. J. Quinn et al. PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. Acta Neuropathologica Communications (2020). PMID 33168089
- Singh A et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European journal of clinical nutrition (2022). PMID 34117375
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
- Liu CF et al. Antiaging Effects of Urolithin A on Replicative Senescent Human Skin Fibroblasts. Rejuvenation research (2019). PMID 30215291
- Aichinger G Natural Dibenzo-α-Pyrones: Friends or Foes?. International journal of molecular sciences (2021). PMID 34884865
- U.S. Food and Drug Administration Agency Response Letter GRAS Notice No. GRN 000791. U.S. Food and Drug Administration (2018). source
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.